Investigational Oral Drug Shows Promise in Genetic Bleeding Disorder

(MedPage Today) — Treatment with engasertib, an investigational oral allosteric selective AKT inhibitor, appears to be safe in patients with hereditary hemorrhagic telangiectasia (HHT), and has been associated with a reduction in the frequency of epistaxis…